Skip to main content
. 2022 Jan 19;7(4):831–840. doi: 10.1016/j.ekir.2022.01.1048

Table 4.

Differences between patients with complete kidney function recovery and those with no recovery

Variables N = 25a n = 6 n = 19 P
Clinical All patients Complete recovery No recovery
Sex, n (%), male 20 (80) 5 (83.3) 15 (78.9) 1
Age, Md (IQR), yr 76 (63–80) 69 (62–76) 76 (65–82) 0.49
HTN, n (%) 23 (92) 5 (83.3) 18 (94.7) 0.43
DM, n (%) 10 (40) 1 (16.7) 9 (47.4) 0.34
Chronic kidney disease, n (%) 10 (40) 1 (16.7) 9 (47.4) 0.1
SCr, Md (IQR), mg/dlb 1.1 (0.9–1.4) 1.1 (0.9–1.1) 1.2 (0.9–1.4) 0.44
 eGFR, Md (IQR), ml/min per 1.73 m2 62 (49–68) 66 (49–87) 62 (49–75) 0.40
Type of anticoagulant, n (%) 0.43
 Vitamin K antagonists 23 (92) 5 (83.3) 18 (94.7)
 Direct-acting oral anticoagulants 2 (8) 1 (16.7) 1 (5.3)
Anticoagulation length, Md (IQR), mo 52 (11–90) 81 (24–93) 48 (11–85) 0.39
INR, Md (IQR) 2.4 (1.6–3.4) 2.0 (1.6–2.6) 2.6 (1.7–3.9) 0.19
AKI stage, n (%) 0.23
 Stage 1 1 (4) 0 1 (5.3)
 Stage 2 3 (12) 2 (33.3) 1 (5.3)
 Stage 3 21 (84) 4 (66.6) 17 (89.5)
SCr, Md (IQR), mg/dl 4.1 (2.8–8.3) 3.4 (2.3–8.3) 4.1 (3–8.3) 0.52
 Peak SCr, Md (IQR), mg/dl 5.2 (3.9–8.7) 6.1 (2.3–10.6) 7.4 (4.2-9.2) 0.61
 Acute dialysis, n (%) 11 (44) 2 (33.3) 9 (47.4) 0.66
Gross hematuria, n (%) 21 (84) 5 (83.3) 16 (84.2) 1
Anticoagulation withdrawal, n (%) 16 (64) 2 (33.3) 14 (73.7) 0.14
 Anticoagulation restart (at discharge), n (%) 12 (75) 2 (100) 10 (71.4) 1
Immunosuppressive treatment (for AKI), n (%) 18 (72) 5 (83.3) 13 (68.4) 0.64
 Corticosteroids, n (%) 18 (72) 5 (83.3) 13 (68.4) 1
 Mycophenolic acid, n (%) 5 (20) 0 5 (26.3) 0.27
Histopathologic6,7,c
IgAN vs. non-IgAN 19/6 5/1 14/5 1
Glomerulosclerosis (0–3) 1 (0–2) 1 (0.5–1) 0 (0–2) 0.28
IFTA (0–6) 3 (2–4) 3 (2–4) 3 (2–4) 1
Arterio- or arteriolosclerosis (absent vs. present) 10/11 3/1 7/10 0.31
Total chronicity score (0–10) 4 (3–5) 4.5 (3–5) 4 (3–5) 0.72

AKI, acute kidney injury; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; IFTA, Interstitial Fibrosis and Tubular Atrophy; IgAN, IgA nephropathy; INR, international normalized ratio; IQR, interquartile range; Md, median; MDRD, Modification of Diet in Renal Disease; SCr, serum creatinine.

Continuous data are expressed as Md (IQR), categorical variables as n (%).eGFR, calculated by MDRD study equation.

a

1 patient excluded (incomplete follow-up).

b

SCr available in the last 12 weeks before admission.

c

22 of 26 biopsies were centrally evaluated.